Arsenic is a human carcinogen whose mechanism of action remains undefined. Based on the hypothesis that arsenic sensitizes cells to mitogenic stimulation by affecting the receptor tyrosine kinase (RTK) signal transduction pathway, these studies first examined the response of fibroblasts to specific mitogens using a defined media system. In both rodent and human fibroblasts, DNA synthesis was found to be stimulated in cells exposed to a transient, sub-lethal concentration of sodium arsenite followed by stimulation with known RTK pathway activators. This effect is observed for up to 32 h after removal of arsenic, suggesting that the RTK pathway is affected in a sustained manner. In contrast, transient arsenic exposure of ras-transformed cells results in decreased mitogen-stimulated DNA synthesis. Flow cytometry indicates that arsenic increases the percentage of wild-type cells in the S-phase of the cell cycle; conversely, the percentage of ras-transformed cells in S-phase is decreased by arsenic. No evidence of arsenic-induced cytotoxicity was detected using the neutral red assay, ensuring that decreased DNA synthesis in ras-transformed cells is not due to cell death. Taken together, the results of experiments presented herein indicate that arsenic produces sustained alterations in the growth characteristics of rodent and human fibroblasts. It is postulated that the proliferation-enhancing effect of arsenic on wild-type cells contributes to its ability to cause cancer.
Arsenic has long been recognized as a human carcinogen, with arsenic ingestion being associated primarily with skin cancer (Schwartz, 1997; Wong et al., 1998) . In India, an estimated 200,000 people have developed pre-cancerous skin lesions due to contamination of drinking water with naturallyoccuring arsenic. The magnitude of exposure translates into millions of people eventually developing basal or squamous cell carcinoma (Bagla and Kaiser, 1996; Das et al., 1994; Mazumder et al., 1998; Saha, 1996; Subramanian, 1996) . There is increasing evidence that arsenic ingestion also causes cancers of the liver, kidney, and bladder, and inhalation of arsenic produces lung cancer, despite the fact that inhaled arsenic is absorbed, distributed, metabolized, and excreted in a manner similar to that of ingested arsenic (Bates et al., 1995; Chen et al., 1992; Chiou et al., 1995; Morris, 1995; Tsuda et al., 1995) . Humans are exposed to arsenic both as a naturallyoccuring component of drinking water and as an environmental contaminant from smelting, semi-conductor, glass, paper, and other industries. Therefore, it is vital to elucidate the mechanism by which arsenic causes cancer in order to more accurately assess the risk to human health and establish rational exposure limits Chappell et al., 1997) .
Although arsenic itself is not mutagenic, some deleterious effects on DNA have been observed, including potentiation of DNA damage by other agents, inhibition of DNA repair, sister chromatid exchange, and gene amplification (Ishinishi et al., 1977; Lee et al., 1988; Lerda, 1994; Li and Rossman, 1989a,b) . However, these effects cannot account completely for the carcinogenic properties of arsenic. On the other hand, arsenic resembles many classic carcinogens in its ability to cause irreversible changes made manifest only after a long latent period. From the available epidemiological and laboratory data, it is clear that arsenic exerts its carcinogenic effects via an atypical mechanism.
The effect of arsenic on cell proliferation provides insight into the mechanism by which arsenic causes cancer. The transient exposure of C3H 10T1/2 cells to sub-lethal concentrations of sodium arsenite results in an enhanced response to subsequent stimulation with sub-optimal levels of serum (Van Wijk et al., 1993) . Components of serum are known to activate the receptor tyrosine kinase (RTK)-type growth factor signal transduction pathway, a universally conserved signaling system whose activation is required for mitogenesis. Therefore, it was hypothesized that arsenic sensitizes cells to mitogenic stimulation by altering the responsiveness of the RTK pathway to ligand binding. Under normal circumstances, a variety of mitogens activates the RTK pathway and stimulates normal cell proliferation (Burgess, 1996; Kramer, 1996; Lewin, 1997; Pitot and Dragan, 1996) . However, unregulated activity of this pathway contributes to malignant transformation. Certain carcinogens are thought to exert their carcinogenic effects by inducing mutations in, or overexpression of, key elements of this pathway (Nagao et al., 1997; Zarbl et al., 1985) , thereby causing growth factor stimulation and the mitogenic response to become uncoupled. For example, constitutive activation of the molecular switch ras can produce transformation in vitro and has been observed in a variety of human and animal tumors in vivo (Bos, 1989) .
The purpose of this study was to determine whether transient arsenic exposure can modulate the mitogenic effect of specific growth factors. These growth factors are known to activate the RTK pathway in both mouse and human fibroblasts as well as in ras-transformed C3H 10T1/2 cells. Our results clearly show that acute arsenic exposure affects the mitogenic response resulting from activation of the receptor tyrosine kinase signal transduction pathway, and that wild-type mouse and human fibroblasts respond similarly. In contrast, the response of rastransformed C3H 10T1/2 cells to arsenic exposure is opposite to that of wild-type cells.
MATERIALS AND METHODS
Cell culture. C3H 10T1/2 fibroblasts were obtained from American Type Culture Collection (Rockville, MD) and cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS), penicillin, and streptomycin (GIBCO/BRL, Grand Island, NY). Defined media consisted of 1:1 DMEM and Waymouth's media, supplemented with ITSϩ (Collaborative Biomedical Products, Bedford, MA), 100 M dexamethasone, and antibiotics. Preliminary experiments indicated that cells cultured in defined media are quiescent but responsive to mitogenic stimulation (data not shown). Human foreskin fibroblast cultures were established as described (Freshney, 1991) and cultured thereafter in DMEM containing 10% FBS.
Preparation of ras-transformed and control C3H 10T1/2 fibroblasts. Using the calcium phosphate method, C3H 10T1/2 murine fibroblasts were transfected with either the eukaryotic expression vector pRC/RSV (Invitrogen) or pRC/RSV containing the v-Ha-ras oncogene (Trouba et al., 1996) . Stable transfectants were isolated by selection in G418 (400 g/ml), and cell transformation was confirmed by morphology and focus-forming ability.
Assessment of DNA synthesis. Quiescent cells cultured to confluence were replated in defined media on fibronectin-coated tissue culture plates. Following a 24-h incubation, cells were treated with 300 M sodium arsenite (Sigma) for 1 h, washed 3ϫ with PBS, and re-fed with defined media. FBS, LPA (lysophosphatidic acid, Sigma), or EGF (epidermal growth factor, Collaborative Biomedical Products or GIBCO/BRL) was added to the cells 8 h after arsenite removal, except where indicated. Eighteen h later, cells were labeled for 2 h with tritiated thymidine. Following addition of trichloroacetic acid, the radioactivity contained in the acid-precipitable material was determined by scintillation counting. Significant differences were determined by analysis of variance followed by application of Fisher's Protected Least Significant Difference (p Ͻ .05) using StatView (Abacus Concepts, Berkeley, CA).
Toxicity determination. Neutral red, which is taken up only by viable cells, was used to ensure that no loss of viability resulted from arsenic pre-treatment (Rossman et al., 1997) . Ras-transformed and control C3H 10T1/2 cells were seeded into 24-well plates (50,000 cells/well) and serumstarved overnight. Cells were treated with 300 M arsenic for 1 h and washed twice before adding serum-free DMEM. Viability was assessed 8 and 26 h later by incubation in the presence of neutral red for 3.5 h at 37°C. Cells were fixed in formaldehyde/CaCl 2 , and dye taken up by viable cells was extracted with ethanol/acetic acid prior to absorbance determination at 540 nm.
Flow cytometric cell cycle analysis. Cell cycle distribution was determined using flow cytometry as described (Vindelov, 1977) . Ras-transformed or wild-type C3H 10T1/2 fibroblasts (1 ϫ 10 6 cells) were cultured overnight in 0.5% FBS/DMEM, treated with 300 M arsenite for 1 h, washed twice with PBS, and re-fed with serum-free DMEM. Eight h later, cells were stimulated with mitogen and harvested at various time points. Cells were resuspended in Vindelov's reagent and analyzed using a FACStar Plus flow cytometer. For each sample, at least 9000 independent events were analyzed, providing a solid statistical basis for determining the percentage of cells in each cell cycle phase using the Lysis II software program.
RESULTS
To determine if arsenic sensitizes the RTK signal transduction pathway to mitogenic stimulation, a defined media system and purified growth factors were utilized. As seen in Figure  1A , C3H 10T1/2 cells cultured in defined media respond in a manner qualitatively similar to that reported by Van Wijk and coworkers (1993) : DNA synthesis in response to sub-optimal serum stimulation is greater in cells pre-treated with a sublethal concentration of sodium arsenite (As) than in control cells. Human foreskin fibroblasts respond in a qualitatively similar manner (Fig. 1B) . Because murine and human cells exhibit a comparable response, the well-characterized C3H 10T1/2 mouse fibroblast cell line can be used as an in vitro model for examining the effect of arsenic on parameters of cell growth. It should be noted that arsenic pre-treatment does not increase the maximal effect of mitogen. In fact, arsenic-treated C3H 10T1/2 cells exposed to the highest concentrations of FBS and EGF exhibit a lower level of thymidine incorporation than do control cells, a result possibly caused by more rapid development of asynchronicity in maximally stimulated cells.
When the RTK pathway activators LPA and EGF were tested in this system, arsenic pre-treatment produced a more pronounced sensitization effect on mitogen-induced DNA synthesis. Figure 2 shows that the effect of sub-optimal concentrations of both LPA (2A and 2B) and EGF (2C and 2D) is potentiated by arsenic pre-treatment in both C3H 10T1/2 cells (2A and 2C) and human fibroblasts (2B and 2D). Because the experimental system utilized limits mitogenic input to the specific mitogens added, it can be concluded that arsenicsensitization is mediated via effects on the RTK signaling pathway. Based on the observation that the sensitization effect is more pronounced when cells are stimulated with LPA or EGF than when stimulated by serum, it appears that the sensitization effect is blunted by undefined elements in serum.
To exert a meaningful effect on mitogen-dependent cell proliferation, the effect of arsenic must be sustained after arsenic removal. To explore the duration of the sensitization effect, the time between arsenic removal and mitogen addition was increased from 8 to 32 h (Fig. 3 ). Upon stimulation with 1 or 3% FBS, a clear arsenic-induced potentiation of DNA synthesis is observed at 8 h, and this trend continues through 32 h. It should be noted that, although the magnitude of mitogenic response decreases over time with a particularly large drop between 8 and 16 h, arsenic pre-treated cells show a greater response than do control cells at each time point. Consistent with the results seen previously, this sustained sensitization effect also is seen at 0.1 and 0.3% FBS, but was lost at 10% FBS (data not shown).
Because the end point in the above studies is incorporation of tritiated thymidine into acid precipitable material, cell cycle analysis was performed to confirm that the arsenic-dependent potentiation of mitogen-induced DNA synthesis is due to an effect on DNA replication rather than DNA repair. Figure 4A clearly illustrates that the proportion of wild-type C3H 10T1/2 cells induced by FBS to enter S-phase is greater in arsenic pre-treated cells than in control cells, even though this parameter is similar between control and arsenic pre-treated cells prior to stimulation (time 0). Similar results were obtained when the RTK pathway activators LPA (panel B) and EGF (panel C) were used to stimulate wild-type C3H 10T1/2 cells. Similarly, arsenic-pretreated human fibroblasts demonstrate a greater proportion of cells entering S-phase than do control cells (data not shown). Therefore, it can be concluded that the increase in mitogen-induced DNA synthesis observed in arsenic pre-treated cells is due to a greater proportion of cells entering the DNA synthesis (S) phase of the cell cycle, and not a result of DNA damage and repair. These data support the hypothesis that the relevant target of arsenic is the RTK signal transduction pathway.
Cells transformed by a mutationally-activated ras oncogene exhibit a constitutively active RTK pathway. Therefore, it was predicted that the effect of arsenic on ras-transformed cells would be quantitatively different from the effect of this metalloid on control cells. In contrast to wild-type cells, arsenic pre-treatment of ras-transformed C3H 10T1/2 fibroblasts produces a decrease in tritiated thymidine incorporation following mitogenic stimulation by LPA (Fig. 5) . Further support for this conclusion was provided by cell cycle analysis, which revealed that arsenic pre-treatment results in a decreased percentage of ras-transformed fibroblasts in S-phase. As shown in Figure 6 , the proportion of cells in S-phase is greater in control (no arsenic pre-treatment) than in arsenic pre-treated cells at times 12, 14, 16, and 18 h following sub-optimal mitogenic stimulation, regardless of whether FBS (Fig. 6A) , LPA (Fig. 6B ), or EGF (Fig. 6C ) is used. The results from cell cycle analysis corroborate and expand the results from the thymidine incorporation experiments, thereby confirming that cells with a constitutively active RTK pathway exhibit an opposite mitogenic response to arsenic pre-treatment than do control cells.
To ensure that the effects of arsenic pre-treatment on rastransformed cells were not due to cytotoxicity, the ability of cells to take up neutral red was assessed. As shown in Figure  7 , no arsenic-induced toxicity is evident in either wild-type or ras-transformed cells at any timepoint (compare each bar to 100%). Thus, the decreased response of ras-transformed cells cannot be attributed simply to cell death.
DISCUSSION
The observation that arsenic modulates RTK signaling is significant because it demonstrates the ability of arsenic to affect a specific and well-characterized mitogenic signal transduction pathway whose aberrant activity is associated with malignant transformation. A key finding of this study is that arsenic sensitizes the mitogenic RTK pathway to subsequent growth-factor stimulation in normal fibroblasts. The RTK signal transduction pathway can be activated by the binding of a variety of growth factors to their cognate receptors; examples include EGF, platelet-derived growth factor, and nerve growth factor. The initial step in signaling is dimerization and tyrosine autophosphorylation of the receptor. Through an adaptor protein, an exchange factor is activated that converts ras p21 to its active state. Ras p21 triggers a complex phosphorylation cascade involving multiple kinases, including raf, MEK, and mitogen-activated protein kinase (MAP kinase). The mitogenic lipid LPA binds to a specific membrane receptor and activates a heterotrimeric G-protein before merging with the RTK pathway (Moolenaar, 1995) . Ultimately, activation of this pathway induces DNA synthesis and cell proliferation. Modulation of pathway activity occurs by crosstalk between it and other G-protein-linked pathways, stress pathways, and cytokine-activated pathways (Kyriakis and Avruch, 1996; Paul et al., 1997; Whitmarsh and Davis, 1996) . Thus, normal regulation of the RTK pathway is complex, making it difficult to establish cause-and-effect relationships. In this study, a defined media system was utilized to limit input from non-RTK sources so that the sensitization effect of arsenic on mitogen-dependent DNA synthesis could be examined in relative isolation. In this manner, it was established that pre-treatment with a sub-lethal
FIG. 2.
Arsenic sensitization of DNA synthesis by RTK activation. Quiescent C3H 10T1/2 mouse cells (panels A and C) or human foreskin fibroblasts (panels B and D) were exposed to sodium arsenite (300 M) for 1 h and stimulated 8 h later with various concentrations of either LPA (panels A and B) or EGF (panels C and D). DNA synthesis was assessed as described in the legend to Figure 1. concentration of sodium arsenite produces a sustained increase in the responsiveness of C3H 10T1/2 cells to receptor-mediated activation of the RTK pathway. Because this effect is evident for up to 32 h after removal of arsenic from the system, it appears that arsenic effects prolonged alterations in mitogenic responsiveness. Possible mechanisms include activation of a positive regulator of the RTK pathway and inhibition of a negative regulator. In contrast, acute arsenic exposure causes immediate activation of the RTK pathway, independent of stimulation with mitogen (Liu et al., 1996) , although delayed ERK activation also has been reported (Ludwig et al., 1998) . Because arsenic is a human-specific carcinogen, it is significant that sodium arsenite pre-treated, primary human foreskin fibroblasts also exhibit increased responsiveness to serum, EGF, and LPA.
Although an appropriate animal model of arsenic-induced carcinogenesis has yet to be developed, the C3H 10T1/2 mouse fibroblast cell line is a well-accepted in vitro model of carcinogenesis induced by metals, including arsenic (Landolph, 1994; Snow, 1992) . In addition, C3H 10T1/2 cells are well characterized and were used extensively in studies leading to the elucidation of the RTK pathway. These characteristics make this cell line uniquely well suited for studying the effect of arsenic on subsequent mitogenic stimulation. The observation that arsenic pre-treatment increases DNA synthesis in C3H 10T1/2 cells following mitogenic stimulation agrees with results described by Van Wijk and coworkers (1993) . Although quantifying tritiated thymidine incorporation into acid-precipitable material provides an index of DNA synthesis, DNA replication cannot be distinguished from DNA repair with this method. Cell cycle analysis clearly demonstrates that arsenic pre-treatment increases the proportion of cells entering the S (DNA synthesis) phase of the cell cycle upon activation of the RTK pathway despite the fact that control and arsenic pretreated cells show similar cell cycle profiles prior to addition of mitogen.
Arsenic can be envisioned to alter RTK pathway activity via a number of different mechanisms. For example, RTK pathway activation down-regulates the EGF receptor (Griswold et al., 1993) , and it can be hypothesized that sodium arsenite inhibits this negative feedback mechanism. Loss of regulation at the growth factor receptor level is predicted to produce an exaggerated effect upon subsequent mitogenic stimulation. In addition, ionizing radiation elicits a stress response similar to that produced by arsenic and also increases EGF receptor expression in both primary human keratinocytes and in A431 cells (Coffer et al., 1995; Peter et al., 1993) ; elevated EGF receptor number is predicted to produce an exaggerated response upon addition of EGF. The observation that the acute stimulatory effect of arsenic on the RTK pathway is a receptor-mediated event (Chen et al., 1998; Liu et al., 1996) supports the hypothesis that changes in the EGF receptor contribute to arsenic sensitization. Alternately, arsenic might interfere with negative regulation of the RTK pathway. MKP-1 (MAP kinase phosphatase-1) and rasGAP (GTPase-activating protein) both attenuate RTK pathway activity, the former by dephosphorylating MAP kinase and the latter by converting ras p21 to its inactive form (Sun et al., 1993; Trahey and McCormick, 1987) . Arsenic inhibits phosphatase activity in vitro, lending credence to the possibility that the sensitization effect of arsenic might be due to inhibition of phosphatases in vivo (Cavigelli et al., 1996; Huang et al., 1995) . Inhibition of MKP-1 can lead to sustained activity of MAP kinase; similarly, inhibition of ras- GAP will allow ras to operate unopposed once the RTK pathway is activated by mitogen. In either case, the result is dysregulation of the RTK signal transduction pathway. In support of this model, preliminary data generated in this laboratory indicate that arsenic exposure causes a decrease in GAP activity accompanied by a slight electrophoretic mobility shift (unpublished observation), results consistent with phosphorylation-dependent inhibition of GAP activity. Regardless of the specific mechanisms involved, the sustained effects of arsenic on RTK signal transduction are likely to contribute to its carcinogenic potential.
Mutational activation of the Ha-ras oncogene produces constitutive activity of the RTK signal transduction pathway because ras p21 is maintained in the active, GTP-bound state (Gibbs et al., 1990) . Based on the observation that arsenic increases the sensitivity of the RTK pathway in wild-type cells, it was anticipated that arsenic pre-treated, ras-transformed cells would display an increased baseline level of DNA synthesis but a minimal increase in sensitivity to mitogenic stimulation as compared to control (no arsenic) cells. Unexpectedly, a decreased level of growth factor-dependent DNA synthesis was seen in response to pre-treatment with sodium arsenite. Although the mechanism has not been defined, this response is consistent with the clinical use of arsenic compounds in the treatment of acute promyelocytic leukemia (Bergstrom et al., 1998; Chen et al., 1997b; Shen et al., 1997; Soignet et al., 1998) . In vitro, treatment of acute promyelocytic leukemia cells with high concentrations of arsenic trioxide results in an apoptotic response, whereas cells exposed to low concentrations undergo growth arrest and partial differentiation (Chen et al., 1997a; Kitamura et al., 1997) . In contrast, cell cycle analysis reveals no evidence of an apoptotic response in ras-transformed C3H 10T1/2 cells pretreated with arsenic, and fewer cells enter the S-phase of the cell cycle. In agreement with these results, arsenic does not induce apoptosis in other cell lines (Chen et al., 1996; Huang and Lee, 1998; Zhang et al., 1998) . It has been suggested that glutathione content is the variable underlying this differential apoptotic response (Dai et al., 1999) . Arsenic is a known stressor, and stress-induced proliferative arrest in human colorectal cancer cells is dependent on the level of p21 (waf1/cip1) , a protein that curbs cell proliferation by inhibiting the cyclin-dependent kinases necessary for cell cycle progression (Macleod et al., 1995) . Comparison of p21 (waf1/cip1) levels between control and ras-transformed cells, as well as the effect of arsenic pre-treatment on this protein, may help to explain their dissimilar response to mitogen treatment. Sodium arsenite also induces expression of the cell cycle arrest protein p53 in transformed human cells (Salazar et al., 1997) , another effect FIG. 7. Lack of cytotoxic effect of arsenic pre-treatment on control and ras-transformed C3H 10T1/2 cells. Quiescent cells were pre-treated with 300 M sodium arsenite as described in the text. Eight h later, one sample was subjected to cytotoxicity analysis (t 8), while the other cells were treated with various concentrations of EGF. Cytotoxicity was assessed 20 h after EGF addition by quantitating the ability of cells to take up neutral red (t 28). Experiments were performed in triplicate, and data is presented as 100 ϫ the average value of the arsenic pre-treated cells divided by the average value of the control cells. Analysis of variance showed that arsenic pre-treatment has no statistically significant effect on increasing cytotoxicity.
FIG. 6.
Inhibitory effect of arsenic on the proportion of ras-transformed C3H 10T1/2 cells in S-phase following mitogenic stimulation. Quiescent cells were pre-treated with 300 M sodium arsenite and treated with mitogen 8 h later. Mitogens used were: A, 3% FBS; B, 1 M LPA; C, 1 ng/ml EGF. Cells were harvested at the indicated time points and cell cycle analysis performed by FACS as described in the text.
which might contribute to the arsenic-dependent inhibition of DNA synthesis seen in this study.
It has been proposed that many of the apparent inconsistencies seen in arsenic carcinogenicity can be resolved by a hypothesis based on the ability of arsenic to induce cell proliferation (Byrd et al., 1996) . In addition to its effect on the cell cycle, arsenic increases the expression of fos and TGF␣, and keratinocytes are induced by arsenic treatment to express interleukin-8 and to overexpress growth factors (Andrews et al., 1987; Germolec et al., 1997 Germolec et al., , 1996 Gubits and Fairhurst, 1988; Yen et al., 1996) . Although not itself mutagenic, arsenicdependent growth enhancement might decrease the efficiency of DNA repair mechanisms, a possibility supported by the observation that arsenic increases DNA damage caused by known mutagens (Rudel et al., 1996) . Alternately, DNA methylation, which plays an essential role in regulation of gene expression, could be compromised in arsenic-treated cells. In fact, two recent in vitro studies have demonstrated both hypermethylation of the tumor suppressor gene p53 (Mass and Wang, 1997) and overall DNA hypomethylation in arsenictreated cell lines (Zhao et al., 1997) . The ability of arsenic to disrupt DNA methylation patterns, in conjunction with arsenicdependent perturbations in the proliferative response, might underlie the unique properties exhibited by this carcinogenic metalloid.
In summary, the results of this study indicate that rastransformed C3H 10T1/2 cells undergo arsenic-dependent growth inhibition, whereas wild-type murine and human fibroblasts are sensitized to mitogenic stimulation. This effect appears to be mediated through the receptor tyrosine kinaselinked signal transduction pathway, thereby providing a rationale for future studies on the response of individual components of this pathway to arsenic exposure. Identification of the relevant molecular target(s) undoubtedly will contribute to elucidating the mechanism by which arsenic causes cancer. This information, in turn, will be invaluable in assessing the potential health effects of arsenic exposure and in formulating regulatory guidelines regarding human exposure to this carcinogen.
